Literature DB >> 6107263

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

P A van Hees, J H Bakker, J H van Tongeren.   

Abstract

Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. In eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107263      PMCID: PMC1419886          DOI: 10.1136/gut.21.7.632

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES
Journal:  Br Med J       Date:  1964-01-11

2.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

3.  Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.

Authors:  H J Pieniaszek
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-11

4.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

5.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

Review 6.  Current concepts: ulcerative proctitis.

Authors:  J H Folley
Journal:  N Engl J Med       Date:  1970-06-11       Impact factor: 91.245

7.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

8.  Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

Authors:  P A van Hees; J H Tuinte; J M van Rossum; J H van Tongeren
Journal:  Gut       Date:  1979-04       Impact factor: 23.059

9.  Ulcerative proctitis and mild ulcerative colitis: A study of 220 patients.

Authors:  M Sparberg; J Fennessy; J B Kirsner
Journal:  Medicine (Baltimore)       Date:  1966-09       Impact factor: 1.889

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  95 in total

1.  Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.

Authors:  E Liang; J Proudfoot; M Yazdanian
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Current medical therapy of inflammatory bowel disease.

Authors:  Kiron M Das; Sherif A Farag
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 3.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 4.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

5.  5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.

Authors:  M B Grisham; D N Granger
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

6.  Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.

Authors:  H Allgayer; J Eisenburg; G Paumgartner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

8.  Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.

Authors:  Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

9.  Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.

Authors:  K R Palmer; J R Goepel; C D Holdsworth
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-16

10.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.